Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015

What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market?

In recent years, several new, high-priced therapies have been approved for the first-line (chemotherapy-naive) treatment of metastatic castrate-resistant prostate cancer (mCRPC), making this lucrative market more dynamic and competitive. The launch of these agents has significantly altered the treatment algorithm and improved the outlook for patients; nevertheless, our research indicates that significant clinical and commercial opportunity remains for therapies that can further prolong overall survival (OS). Several therapies are in late-stage development for first-line (chemotherapy-naive) mCRPC, although we do not anticipate that all of them will be approved for this indication.

Contact sales account_box

Report

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…

north_east

Report

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…

north_east

Report

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…

north_east

Report

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

north_east

Product logins

Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015

Related Market Assessment Reports

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Follow us

Contact us